Corporate carve-outs
Pharma to NewCo
Non-core or under-resourced pharma assets spun into focused vehicles where the parent retains equity, milestones, royalties, or option rights.
Hong Kong (HQ)ShanghaiZurichChicago
HKG time - 14:32 HKTEN/ZHLinkedIncontact@visionlifesciences.com
Services / NewCo Formation
Service / 04 / 04
Form asset-centric NewCos built for capital and exit.
Partner with Vision Lifesciences to spin therapeutics, platforms, and under-resourced assets into focused NewCos. We advise on asset selection, structure, capital narrative, investor access, and launch execution.
Model
Asset-centric
Capital
Global syndicate
Operating
Lean launch
What we deliverv.2026
- Asset Stress-TestEvaluate technical, IP, CMC, clinical, and commercial readiness before committing to a spinout path.
- Structure DesignDefine IP license or assignment, cap table, governance, retained rights, milestones, royalties, and exit optionality.
- Capital NarrativeTranslate the asset into an investor-ready story with clear use of proceeds, value inflection, and acquisition logic.
- Investor & Operator SearchSource specialized capital, fractional executives, CRO/CMO partners, and strategic counterparties.
- Formation LaunchCoordinate entity setup, workplan, data room, operating model, and first 100-day execution path.
Why us
What NewCos need before they raise capital.
Strong NewCos start before incorporation: clean IP, focused capital use, credible leadership, a fundable data package, and a clear exit thesis.
01
NewCos are built to focus capital
The goal is not simply a new legal entity. It is an asset-centric vehicle with a clean thesis, focused budget, and milestones investors can underwrite.
02
Structure determines fundability
A promising asset can become unfinanceable if the license is too narrow, the parent retains too much control, or the cap table blocks future syndicates.
03
Global formation is a BD process
Cross-border NewCos need scientific diligence, venture syndication, operating leadership, and a future acquirer map from day one.
Approach
How our NewCo formation process works.
From asset selection to launch, we help clients decide whether a NewCo is the right path and then design the vehicle around capital, data, and exit.
01
Asset Selection
We evaluate which assets merit a NewCo path based on data package, IP control, development cost, market opportunity, and strategic fit.
02
Formation Architecture
We design the corporate structure, license terms, retained economics, board model, and operating system.
03
Capital & Team Build
We source investors, fractional executives, scientific advisors, CRO/CMO partners, and strategic validators.
04
Launch & First Milestones
We support entity formation, data-room readiness, workplan launch, and first value-inflection milestones.
Readiness framework
Six questions before forming the entity.
A NewCo should not be formed around optimism. It should be formed around diligence that investors, operators, and future acquirers can inspect.
/ 01
Data Package
Proof of concept, reproducibility, translational rationale, data audit trail, and clinical readout plan.
/ 02
IP Control
Field-of-use, sublicensing rights, improvements, assignment vs. license, and freedom to operate.
/ 03
CMC Path
Manufacturing process, scalability, CMO readiness, quality system, and regulator-facing documentation.
/ 04
Capital Need
Use of proceeds, runway, value-inflection point, investor milestone, and exit financing requirement.
/ 05
Leadership
Minimum viable management team, fractional executives, scientific advisory, and board composition.
/ 06
Exit Logic
Likely acquirers, option partners, licensing route, IPO path, and what data those buyers need to see.
Formation corridors
Where the NewCo model creates leverage.
We use the NewCo model when focus, dedicated capital, and independent governance can unlock more value than leaving an asset inside the parent.
Academic translation
University to NewCo
Patent-centric spinouts that need industrial-grade diligence, translational strategy, and investor-ready development plans.
Cross-border assets
Asia / EU / US formation
High-potential assets sourced across regions and formed into investable vehicles in the jurisdiction best suited to capital, team, and exit path.
Structures
NewCo architectures we commonly advise on.
Formation design balances focus, shared infrastructure, parent economics, investor control, and future exit flexibility.
Single lead program
Asset-centric NewCo
A focused company built around one high-conviction asset with clear development milestones and acquisition logic.
Shared infrastructure
Hub-and-spoke
A central platform provides legal, finance, CMC, and operating support to multiple asset-specific entities.
Strategic sponsor
Option-backed NewCo
A pharma or strategic investor funds the NewCo while retaining option or right-of-first-negotiation economics.
Patent-centric
Academic spinout
A university or inventor-backed vehicle formed around foundational IP with dedicated translational capital.
Coverage
What we pressure-test before formation.
Each NewCo model depends on a different mix of diligence, capital, leadership, and exit readiness. We make those dependencies explicit.
Data
IP
CMC
Capital
Team
Exit
Corporate carve-out
Academic spinout
Cross-border NewCo
Platform vehicle
Option-backed
Virtual biotech
Illustrative engagements
What a NewCo formation mandate looks like.
Anonymized vignettes drawn from past carve-out, spinout, and formation work. Specific assets, investors, and economics are confidential and subject to NDA.
Corporate portfolio to NewCoCONFIDENTIAL / NDA
Pharma carve-out / oncology
BriefA pharma owner wanted to advance a promising but deprioritized oncology program without increasing internal development burden.
Our roleAssessed IP and CMC readiness, structured retained economics, mapped investor syndicate, and built the first 100-day operating plan.
OutcomeNewCo formed with external capital and parent retaining equity plus downstream economics.
University-originated IPCONFIDENTIAL / NDA
Academic spinout / rare disease
BriefInventor group needed to move a discovery from grant-funded research into an investable translational vehicle.
Our roleCreated formation thesis, mapped FTO gaps, recruited fractional CMO support, and prepared investor materials.
OutcomeSeed financing process launched with industrial-grade diligence package.
Asia-origin asset to global vehicleCONFIDENTIAL / NDA
Cross-border NewCo / cell therapy
BriefAsset owner wanted global development capital while preserving regional strategic rights.
Our roleDesigned regional rights split, venture financing story, operating model, and potential acquirer map before incorporation.
OutcomeFormation plan approved; investor and executive search initiated.
Engagement model
We form companies around investable clarity.
Formation work is multidisciplinary: science, IP, CMC, capital, talent, governance, and exit strategy. We keep those threads connected.
Formation before fundraising
We resolve the asset, IP, CMC, and governance questions before investor outreach. Investors fund clarity, not loose optionality.
Built-to-buy planning
Every development plan is linked to the likely acquirer or partner universe and the data package they will need to underwrite.
Capital-efficient operating model
We design lean NewCo operations around CRO/CMO leverage, fractional leadership, and milestone-based spend.
Parent and investor alignment
We balance parent-company retained rights with investor requirements for independence, governance, and exit flexibility.
Frequently asked
What teams ask before forming a NewCo.
01What makes an asset suitable for NewCo formation?+
The asset needs a clear value-inflection milestone, controllable IP, a credible development path, and enough strategic relevance for investors or future acquirers to underwrite.
02Is a NewCo better than out-licensing?+
Not always. NewCo formation is useful when focused external capital and dedicated management can create more value than a direct license today. If the asset is already ready for a strong licensing process, out-licensing may be cleaner.
03Can the parent retain rights or equity?+
Yes. Parents commonly retain equity, milestones, royalties, options, regional rights, or rights of first negotiation. The key is keeping the NewCo independent enough to attract capital.
04Do you help source management?+
Yes. We help identify fractional executives, scientific advisors, board candidates, CRO/CMO partners, and operating support appropriate to the asset stage.
05How long does formation take?+
A serious formation process usually takes three to six months before launch or financing, depending on IP complexity, diligence readiness, investor appetite, and management search.
Engage
Assess a specific NewCo candidate under NDA.
Share the asset, data package, IP position, parent objectives, and expected value-inflection milestone. A partner will respond within one business day with a confidential first conversation.
RESPONSE WITHIN 24 HOURS / NDA-FIRST